BPC-157 Research: Mechanism, Models & Sourcing

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide. In the literature it is most often described as a partial sequence derived from a protein identified in gastric juice, which is why researchers frequently refer to it as a "stable gastric pentadecapeptide." Its reported chemical sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight near 1419 Da.

Within research settings, BPC-157 has been characterized for its stability in aqueous and acidic conditions and is commonly used as a reference compound in studies of tissue-repair signaling. VANTA supplies BPC-157 strictly as a reference material for in-vitro and laboratory research. It is not a drug, supplement, or food, and nothing on this page should be read as guidance for human or veterinary administration.

Studied mechanisms in the literature

Published preclinical work has examined several candidate pathways that researchers associate with BPC-157 activity. A recurring theme in the literature is modulation of the nitric oxide (NO) system: investigators have reported interactions with endothelial nitric oxide synthase (eNOS) signaling, including studies describing effects on the Src-Caveolin-1-eNOS axis in vascular endothelial cell models.

Other reports have examined angiogenesis-related signaling and the expression of growth-factor and receptor genes in cultured cells, such as upregulation of growth-hormone-receptor expression in tendon fibroblasts. Additional mechanistic papers discuss pathways including FAK-paxillin, JAK-2, and Egr-1 in various model systems. These are described in the literature as observed associations in experimental models, and the precise mechanism of action remains an active area of investigation.

Research models and reported findings

BPC-157 has been studied across a broad set of animal and in-vitro models, with findings reported in a hedged, model-specific way rather than as established outcomes. Musculoskeletal models are well represented: researchers have examined tendon, ligament, muscle, and tendon-to-bone preparations, with papers describing modulated angiogenesis and tendon explant outgrowth in rat-derived tissue.

Gastrointestinal models form another large body of work, where the peptide has been studied in the context of mucosal-integrity research and so-called cytoprotection in rodent gastric-lesion models. A separate strand of literature has explored brain-gut axis signaling, including reported interactions with serotonergic, dopaminergic, and GABA systems in experimental animals. These reports describe what was observed in specific laboratory models and should not be generalized beyond those research contexts.

Handling and reference notes for researchers

BPC-157 is typically supplied as a lyophilized powder for laboratory reconstitution. Researchers generally store the sealed lyophilized vial cold and protected from light, and reconstitute with an appropriate solvent immediately before experimental use, following their own institutional protocols.

Accurate experimental work depends on knowing exactly what is in the vial: the true peptide identity, its purity, and the actual peptide content by mass. Because research-grade peptides can vary between suppliers, independent analytical verification is the relevant control for reproducible work. The notes here are general reference points for laboratory handling and are not instructions for any in-vivo or human application.

How VANTA verifies it

VANTA treats analytical verification as the core of a reference-grade supply. Each lot of BPC-157 is assessed by reversed-phase HPLC to quantify chromatographic purity, with our specification targeting high purity so researchers can attribute results to the peptide rather than to contaminants.

Identity is confirmed by mass spectrometry, which checks that the measured mass matches the expected pentadecapeptide and that the correct molecule was synthesized. Every batch ships with a per-batch Certificate of Analysis (COA) documenting the HPLC purity result, the mass-spec identity confirmation, and lot-level details. This per-lot documentation lets a laboratory tie each experiment to a specific, traceable batch and the data behind it.

Compliance and intended use

All BPC-157 supplied by VANTA is sold for laboratory and research use only. It is not approved or labeled for human consumption, clinical use, diagnostic procedures, or as a therapeutic agent, and the research framing on this page does not constitute medical or veterinary advice.

The studies referenced here were conducted in animal or in-vitro models. Findings from such models do not establish safety or effect in humans and are summarized only to orient researchers to the existing literature. Researchers are responsible for complying with all applicable institutional, local, and national regulations governing the acquisition, handling, and use of research peptides.

BPC-157: A Research Reference for the Stable Gastric Pentadecapeptide